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Molecular Medicine
Human Skeletal Muscle Drug Transporters Determine Local
Exposure and Toxicity of Statins
Michael J. Knauer, Bradley L. Urquhart, Henriette E. Meyer zu Schwabedissen, Ute I. Schwarz,
Christopher J. Lemke, Brenda F. Leake, Richard B. Kim, Rommel G. Tirona
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Rationale: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, are important drugs used
in the treatment and prevention of cardiovascular disease. Although statins are well tolerated, many patients
develop myopathy manifesting as muscle aches and pain. Rhabdomyolysis is a rare but severe toxicity of statins.
Interindividual differences in the activities of hepatic membrane drug transporters and metabolic enzymes are
known to influence statin plasma pharmacokinetics and risk for myopathy. Interestingly, little is known
regarding the molecular determinants of statin distribution into skeletal muscle and its relevance to toxicity.
Objective: We sought to identify statin transporters in human skeletal muscle and determine their impact on statin
toxicity in vitro.
Methods and Results: We demonstrate that the uptake transporter OATP2B1 (human organic anion transporting
polypeptide 2B1) and the efflux transporters, multidrug resistance–associated protein (MRP)1, MRP4, and
MRP5 are expressed on the sarcolemmal membrane of human skeletal muscle fibers and that atorvastatin and
rosuvastatin are substrates of these transporters when assessed using a heterologous expression system. In an in
vitro model of differentiated, primary human skeletal muscle myoblast cells, we demonstrate basal membrane
expression and drug efflux activity of MRP1, which contributes to reducing intracellular statin accumulation.
Furthermore, we show that expression of human OATP2B1 in human skeletal muscle myoblast cells by
adenoviral vectors increases intracellular accumulation and toxicity of statins and such effects were abrogated
when cells overexpressed MRP1.
Conclusions: These results identify key membrane transporters as modulators of skeletal muscle statin exposure
and toxicity. (Circ Res. 2010;106:297-306.)
Key Words: statins 䡲 drug transporters 䡲 myopathy

H

ates of mevalonate in the development of statin-induced
myotoxicity.10 In addition to decreased cholesterol synthesis,
HMG-CoA reductase inhibition by statins causes a commensurate reduction in the levels of downstream metabolic
products including isoprenoids, dolichol, and ubiquinone
(coenzyme Q10).10 –13 Among these are the isoprenoid secondary metabolic intermediates geranylgeranylpyrophosphate and farnesylpyrophosphate that are involved in protein
isoprenylation and activation of small GTPases such as Rho
and Rab. The important role for diminished isoprenylation in
the mechanism of statin myotoxicity is related to induction of
the muscle atrophy-linked protein atrogin-1.12 This is highlighted by the findings that supplementation of geranylgeranylpyrophosphate to cultured skeletal myotubes or isolated
myofibers treated with statins leads to attenuation of toxicity,11,13–15 whereas inactivation of a Rab and RhoA induces
toxicity.11,13 Decreased geranylgeranylation of small GT-

MG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, statins, are highly effective drugs for
the treatment of hypercholesterolemia, a major risk factor of
cardiovascular disease. Statins inhibit the synthesis of mevalonate, the rate-limiting step in cholesterol biosynthesis.1,2
Although statins are generally well tolerated,3 skeletal muscle
side effects are commonly reported among those treated. One
such side effect, myalgia, which is defined as muscle aches or
weakness in the absence of blood creatine kinase elevation,
occurs in 5% to 15% of statin-treated patients.2,4 – 8 In rare
cases, potentially life-threatening statin-induced rhabdomyolysis may occur, a condition characterized by acute muscle
damage, resulting in pronounced elevation in creatine kinase
levels and possible renal failure.9
The pathophysiology of statin-induced myopathy is not
completely understood. The leading mechanism suggests a
role for cellular depletion of secondary metabolic intermedi-
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Non-standard Abbreviations and Acronyms
BCRP
HMG-CoA
HSMM
MRP
OATP
OAT
P-gp

breast cancer resistance protein
3-hydroxy-3-methylglutaryl coenzyme A
human skeletal muscle myoblast
multidrug resistance–associated protein
organic anion transporting polypeptide
organic anion transporter
P-glycoprotein
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Pases by statins appears to stimulate the mitochondrial
apoptotic cell death pathway in skeletal myotubes.13,15 In
addition to isoprenoids, coenzyme Q10 levels in plasma16 and
skeletal muscle17 are decreased with statin treatment. Although depletion of coenzyme Q10 is thought to affect
oxidative phosphorylation and protection from statin-induced
oxidative stress, compelling clinical evidence is lacking
regarding the efficacy of coenzyme Q10 treatment of statin
myopathy.18 There is recent evidence to indicate that fatty
acid oxidation is perturbed in cultured myotubes of statin
intolerant (myalgic) patients,19 a finding that differs from
patients with rhabdomyolysis.20 Such data suggest that the
mechanisms of statin toxicity are different between those
affected with myalgia and rhabdomyolysis.
It is well documented that myotoxicity is statin dosedependent, and myopathy risk increases when statins are
coadministered with drugs that either interact to increase
plasma statin levels or themselves have propensity for muscle
damage.21–24 Indeed, macrolide antibiotics and azole antifungals are well-known drug inhibitors of hepatic statin metabolism via cytochrome P450 enzymes, dramatically increasing
plasma statin levels.21,24,25 Moreover, inhibition of statin liver
uptake (transport) mediated by multiple members of the
organic anion transporting polypeptide (OATP) family by
drugs such as gemfibrozil, cyclosporine A and rifampin can
elevate drug levels.24,26 –29 Furthermore, we have previously
reported that a common genetic polymorphism resulting in a
single nucleotide difference in the SLCO1B1 gene encoding
hepatic OATP1B1 (521C⬎T, V174A; rs4149056)30 is associated with increased plasma levels of a number of statins.31
In a genome-wide association study, the rs4149056 polymorphism in SLCO1B1 was found to be the most robust
predictor of the risk for simvastatin-induced myopathy.32 In
addition, efflux transporters in liver that mediate secretion of
statins into bile could play a role in risk for statin myopathy.
For example, genetic variation in the statin biliary efflux
transporters multidrug resistance–associated protein (MRP)2
and breast cancer resistance protein (BCRP) is associated
with variability in pravastatin and rosuvastatin plasma levels,
respectively.33–35
Despite that the currently marketed statins have varying
physicochemical characteristics, membrane transporters that
act to facilitate drug uptake or efflux in tissues appear to have
significant influence on the pharmacokinetics of most statins.
This is evidenced by marked changes in plasma drug levels
following transporter inhibition or through their attendant

genetic polymorphisms.36,37 Considerable attention has been
given to drug transporters in the small intestine, kidney, and
liver, which affect systemic exposure to statins. However,
there is a paucity of studies that have examined statin
transporters within skeletal muscle and their influence on
myotoxic side effects of statins, despite that this has been
considered conceptually.4 Given that plasma drug levels do
not entirely predict risk for statin myopathy,38 we hypothesize
that factors which control local skeletal muscle statin concentrations, such as muscle transporters, may be more relevant. Specifically, we propose that the interplay between
statin uptake versus efflux transporters modulates the response to skeletal muscle statin exposure.
In this study, we identify drug transporters in human
skeletal muscle that affect the distribution of 2 prototypic
lipophilic and hydrophilic statins, atorvastatin and rosuvastatin. We demonstrate that the uptake transporter, OATP2B1,
and the efflux transporters, MRP1, MRP4, and MRP5 are
expressed in skeletal muscle and are capable of transporting
atorvastatin and rosuvastatin. Importantly, we show that by
affecting drug transporter activity in a model of human
skeletal muscle, statin toxicity can be modulated.

Methods
An expanded Methods section is available in the Online Data
Supplement at http://circres.ahajournals.org.

Gene Expression Analysis
Tissue and cell culture expression of transporters was determined by
quantitative polymerase chain reaction, and Western blotting and
immunofluorescence microscopy were performed as described in the
Online Data Supplement.

Identification of Statin Transporters
Heterologous expression of transporters in human cervical cancer
cells (HeLa) by recombinant vaccinia virus method and statin
transport activity assays were performed as described previously39
with modifications detailed in the Online Data Supplement.

Statin Accumulation and Toxicity in Skeletal
Muscle Cells
Overexpression of transporters in cultured primary differentiated
human skeletal muscle myoblast (HSMM) (Lonza, Walkersville,
Md) cells by adenoviral gene delivery, statin cellular accumulation
assays, as well as toxicity assays (ATP content, mitochondrial
methylthiazolyldiphenyl-tetrazolium bromide reduction, caspase 3/7
activation) are described in detail in the Online Data Supplement.

Results
Identification of Statin Transporters in
Skeletal Muscle
Little is known about the expression of drug transporters in
human skeletal muscle. Therefore, we screened a cDNA
library of human skeletal muscle for expression of a wide
variety of drug transporters including OATPs, organic anion
transporters (OATs), organic cation transporters, MRPs,
BCRP, and P-glycoprotein (P-gp). The known statin uptake
transporters such as OATP1B1, OATP1B3, OAT1, and
OAT3,40 – 45 as well as efflux transporters such as MRP2,
P-gp, and BCRP,33,42,46 – 48 were not detected in skeletal
muscle (not shown). However, we detected mRNA expression of the known statin uptake transporter OATP2B1 (Figure
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Figure 1. Expression of uptake and efflux transporters in various human tissues and HSMM cells. A, Relative mRNA gene expression of
MRP1, MRP2, MRP4, MRP5, BCRP, and OATP2B1 in a range of human tissues and cultured HSMM cells. Expression was normalized
to expression in human skeletal muscle. B, Protein expression of MRP1, MRP4, MRP5, and OATP2B1 in human skeletal muscle and
cultured HSMM cells by Western blot. Lysates from HeLa cells transfected with blank vector or transporter cDNA served as negative
and positive controls, respectively. In the MRP4 blot, one lane was cropped as denoted by the dividing line. C, Cellular localization of
MRP1, MRP4, MRP5, and OATP2B1 in normal human skeletal muscle was determined by immunofluorescence confocal microscopy.
Transporters are shown in green, whereas nuclei are shown in blue. Scale bar⫽50 m.

1A).40,49 The mRNA level of OATP2B1 was highly detectable in skeletal muscle, although it is significantly lower than
tissues with very high expression (liver, kidney and small
intestine). Given that MRP2 transports statins, the expression
of other members of this efflux transporter family was
examined revealing high expression of MRP1, MRP4, and
MRP5 in skeletal muscle. Quantitative mRNA analysis and
Western blot confirmed the expression of these drug transporters in human skeletal muscle (Figure 1A and 1B).
Immunolocalization of OATP2B1, MRP1, MRP4, and MRP5
in normal human skeletal muscle by confocal microscopy
demonstrated that each was expressed on the sarcolemmal
membrane (Figure 1C).
We then determined whether the transporters identified in
skeletal muscle were capable of statin transport using a
recombinant (vtf-7) vaccinia virus overexpression system in a
human cervical cancer cell line (HeLa).39 As we previously
described, OATP2B1 is capable of rosuvastatin transport40
and here we confirm that atorvastatin is also a transport
substrate (Figure 2).49,50 Indeed, in this model, OATP2B1
increases the cellular accumulation of rosuvastatin and atorvastatin by 2-fold. Although OATP2B1 is the relevant trans-

porter for uptake of statins into skeletal muscle, we present
new and confirming data that other OATPs (1B1, 1B3 and
1A2) transport both atorvastatin and rosuvastatin (Figure 2).
It should be noted that the differences in statin transport
between OATP2B1 and other transporters as shown in this
model (Figure 2) likely do not reflect the relative statin
uptake efficiencies in vivo, because transporter expression
was not normalized and the absolute expression of these
transporters in different tissues is undetermined.
Drug interactions involving inhibition of the major liver
OATPs (1B1 and 1B3) are associated with elevated plasma
statin levels. Similarly, OATP2B1 is susceptible to inhibition
by coadministered medications.51 Here, we show that stimulated intracellular accumulation of atorvastatin and rosuvastatin by OATP2B1 is attenuated after coincubation with
cerivastatin, gemfibrozil, gemfibrozil-glucuronide, fenofibrate, rifampin, and glyburide (Figure 3). Interestingly, incubation with cyclosporine A caused a significant reduction in
rosuvastatin accumulation but increased atorvastatin levels
(Figure 3).
The transport efficiency of human OATPs compared to
rodent OATPs is lower in this experimental system.40 For
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Figure 2. Intracellular accumulation of statins in HeLa cells transiently transfected with various uptake drug transporters. Intracellular accumulation of [3H]rosuvastatin and [3H]atorvastatin in
cells expressing OATP2B1, OATP1B1, OATP1B3, OATP1A2,
OAT3, and rOatp1b2. Results are presented as femtomoles per
microgram of protein⫾SEM (n⫽3). *P⬍0.05, **P⬍0.01, ***P⬍0.001
compared to vector control. The presence (⫹) or absence (⫺) of
transporter expression in various tissues is shown below.

instance, the rat ortholog of the human transporters
OATP1B1 and OATP1B3, rOatp1b2, appeared capable of
mediating a significantly greater accumulation of rosuvastatin
and atorvastatin into cells using this technique, in relation to
human OATP2B1 (Figure 2). For this reason, we used
rOatp1b2 as the model transporter to maintain statin uptake
into cells thereby allowing for the identification of pertinent
transporters capable of statin efflux (see below).
Although highly expressed in skeletal muscle, it was not
known whether MRP1, MRP4, or MRP5 transported statins.
Hence, HeLa cells were double transfected with the uptake
transporter rOatp1b2 and various efflux transporters. In this
system, modulation of cellular retention of atorvastatin or
rosuvastatin served as an indicator for efflux transport activity. Indeed, we confirm that rosuvastatin and atorvastatin are
transported by MRP2, P-gp, and BCRP using this double
transporter (uptake/efflux) transfection system (Figure 3).
Rosuvastatin retention in cells expressing rOatp1b2 together
with MRP1, MRP4, or MRP5 was lower (77%, 80%, and
27% lower, respectively) than cells expressing rOatp1b2
alone (Figure 4). This was also true for atorvastatin when

Figure 3. Chemical inhibition of statin uptake by OATP2B1 in
transiently transfected HeLa cells. Intracellular accumulation of
[3H]rosuvastatin and [3H]atorvastatin in cells expressing
OATP2B1 (gray bars) cotreated with cerivastatin, gemfibrozil,
gemfibrozil-glucuronide, fenofibrate, rifampin, glyburide, or cyclosporine A at 100 mol/L. Results are presented as femtomoles per microgram of protein⫾SEM (n⫽3). *P⬍0.05,
**P⬍0.01, ***P⬍0.001 compared to OATP2B1 DMSO treatment.

MRP1 and MRP4 (63 and 47% lower, respectively), but not
MRP5, were double transfected with rOatp1b2. These findings demonstrate that MRP1, MRP4, and MRP5 are novel
statin transporters.

Statin Disposition in an In Vitro Model of Human
Skeletal Muscle
To evaluate the role of statin transport in toxicity, we used
differentiated, primary human skeletal muscle myoblast
(HSMM) cells as an in vitro model. First, we assessed
whether HSMM cells expressed statin efflux transporters and
found that MRP1, MRP4, and MRP5 are constitutively
expressed (Figure 1A and 1B), whereas MRP2, BCRP, and
P-gp are absent. Cellular localization studies revealed that
some MRP1 is expressed on the cell surface of HSMM cells,
although significant levels of the transporter are found in
intracellular spaces. By contrast, MRP4 and MRP5 are not
found on the plasma membrane, but localize within the Golgi
in HSMM cells (Figure 5A). To test whether functional MRP
activity is present in HSMM cells, statin accumulation was
examined after chemical inhibition of efflux transport. When
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Figure 4. Intracellular accumulation of statins in HeLa cells transiently transfected with rOatp1b2 and various efflux drug transporters. Intracellular accumulation of [3H]rosuvastatin and
[3H]atorvastatin in HeLa cells expressing rOatp1b2 and/or
MRP1, MRP2, MRP4, MRP5, P-gp, or BCRP. Results are presented as percentages of rOatp1b2-mediated uptake⫾SEM
(n⫽3 to 8). ***P⬍0.001 compared to vector control and efflux
transporter alone; †††P⬍0.001 compared with rOatp1b2 mediated uptake. The presence (⫹) or absence (⫺) of transporter
expression in various tissues is shown below.

HSMM cells were coincubated with known MRP inhibitors
MK-571,52 dipyridamole,53 quercetin,54 or verapamil,55 there
was a significant increase in cellular retention for both
atorvastatin and rosuvastatin when compared to cells treated
with vehicle (Figure 5B). Together with membrane localization studies, the results indicate that HSMM cells natively
express functional MRP1 transporter whose activity determines the intracellular accumulation of statins. Coincubation
with cerivastatin also significantly increased the cellular
retention of atorvastatin and rosuvastatin in HSMM cells
(Figure 5B), suggesting that this statin interacts with and is a
possible substrate of MRPs. With respect to statin uptake,
none of the known statin uptake transporters was expressed in
HSMM cells, and, importantly, OATP2B1 is not expressed
despite that it is present in vivo (Figure 1).

Role of Transporters in Statin Toxicity in an In
Vitro Model of Human Skeletal Muscle
We next examined the effect of transporters on skeletal
muscle exposure and toxicity of statins. In this experiment,

Skeletal Muscle Statin Transport and Toxicity
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we overexpressed OATP2B1 and MRP1 in HSMM cells
using adenoviral vectors (Ad-OATP2B1 and Ad-MRP1, respectively). Examination by confocal microscopy demonstrated robust overexpression of these transporters in HSMM
cells (Figure 6). There was significant plasma membrane
expression of MRP1, whereas for OATP2B1 there was some
transporter on the cell membrane, but the majority was
confined intracellularly.
Adenoviral overexpression of OATP2B1 in HSMM cells
caused a significant increase in the cellular retention of both
atorvastatin and rosuvastatin over 60 minutes (Figure 6B).
After transduction with Ad-OATP2B1 and Ad-MRP1, the
cellular retention of both rosuvastatin and atorvastatin were
significantly attenuated compared to Ad-OATP2B1 alone.
Transduction with Ad-MRP1 alone did not significantly
reduce the levels of rosuvastatin in HSMM cells; however,
there was a trend toward reduced atorvastatin accumulation.
Consequently, the effect of statin efflux transporters on
intracellular statin levels is not pronounced in the absence of
influx transporters. These results indicate that overexpression
of OATP2B1 and MRP1 leads to changes in intracellular
statin levels in an HSMM cell model.
Preliminary studies were performed to define the time- and
concentration dependency for atorvastatin and rosuvastatin
cytotoxicity in HSMM cells. Cell viability, as evaluated by
intracellular ATP levels, declined after 5 days of statin
treatment. At comparable concentrations (eg, 100 mol/L),
atorvastatin was more toxic than rosuvastatin (Figure 7A).
The cytotoxicity of atorvastatin and rosuvastatin in HSMM
cells after adenoviral-mediated transporter gene delivery was
assessed by 2 measures of mitochondrial function, ATP
content and MTT reduction to formazan (Figure 7B through
7D), as well as activation of Caspases 3/7, a marker of
apoptosis induction (Figure 7D). Transduction of HSMM
cells with Ad-OATP2B1 sensitized HSMM cells to atorvastatin toxicity as demonstrated by signals from all 3 toxicity
end-points (Figure 7B through 7D). There was a similar trend
for rosuvastatin toxicity but only the increased activity of
caspases 3/7 reached statistical significance (Figure 7D). This
result is likely because overexpressed OATP2B1 was not
well localized on the plasma membrane, leading to modest
elevation of intracellular statin concentrations. Similarly,
when HSMM cells were transduced with Ad-MRP1 alone,
there was a lack of effects on statin cytotoxicity, consistent
with the absence of significant changes in intracellular statin
accumulation. However, when cells were transduced with
both Ad-OATP2B1 and Ad-MRP1, there was protection
against toxicity by both statins when compared to HSMM
cells transduced with Ad-OATP2B1 alone to viabilities similar to those cells transduced with Ad-MRP1 alone (Figure 7B
through 7D). Taken together, these results indicate that
OATP2B1 expression promotes statin toxicity, whereas
MRP1 is cytoprotective in human skeletal muscle cells.

Discussion
Drug transporters have recently been implicated in statininduced myopathy. However, those that have been previously
considered have been the transporters located in the liver and
small intestine, which are largely responsible for controlling

302

Circulation Research

February 5, 2010

Downloaded from http://ahajournals.org by on June 21, 2022

Figure 5. A, Immunofluorescence localization of MRP1, MRP4, and MRP5 (green), Golgi (red), and nuclei (blue) in differentiated
HSMM cells using confocal microscopy. Scale bar⫽20 m. B, Intracellular accumulation of [3H]rosuvastatin and [3H]atorvastatin
after 30 minutes in HSMM cells cotreated with or without 100 mol/L cerivastatin or the nonspecific MRP inhibitors dipyridamole,
MK-571, quercetin, and verapamil at 100 mol/L. Results are presented as percentages of DMSO control⫾SEM (n⫽3 to 4).
**P⬍0.01, ***P⬍0.001 compared with DMSO control.

plasma statin concentrations. Indeed, genetic polymorphisms
in the hepatic statin uptake transporter, OATP1B1, leading to
reduced transport function are associated with a dramatic
increase in risk for simvastatin-related myopathy.32 Moreover, inhibition of both OATP1B1 and liver glucuronidation
activity by concomitant treatment with the antilipidemic drug
gemfibrozil causes elevation of cerivastatin plasma concentrations conferring greater predisposition to rhabdomyolysis.29,56 Although high plasma statin level is thought to be a
risk factor, it does not entirely predict myopathy. In fact, there
are individuals who exhibit high statin plasma levels but do
not develop myopathy, suggesting that other factors including
skeletal muscle fiber statin concentration may have an impact
on side effect risk.38 Despite the recognition that drug
transporters control intracellular statin concentrations, the
relevant transporters in human skeletal muscle have long
been overlooked.
In this report, we identified drug transporters in human
skeletal muscle capable of transporting statins. Previous
reports have shown that OATP2B1 is a high-affinity uptake
transporter for both atorvastatin and rosuvastatin.40,49
OATP2B1 is expressed on the apical and basolateral membranes of enterocytes and hepatocytes, respectively, and
contributes to the oral absorption and hepatic distribution of
statins. In addition, OATP2B1 is localized on the plasma
membrane of cardiac endothelial cells,49 as well as in platelets,50 where it is thought to be involved in the pleiotropic
cardiovascular effects of statins. Here, we show for the first

time, OATP2B1 is similarly expressed on human skeletal
muscle sarcolemmal membrane. These findings are consistent
with a report that suggested the presence of Oatp1a4 and
Oatp2b1 in rat skeletal myofibers at the mRNA level.57
However, demonstration of rat Oatp1a4 and Oatp2b1 protein
expression in muscle was not confirmed, nor were data
presented to show that these transporters mediate statin
uptake.57 Despite that direct measurement of statin accumulation was not monitored, cotreatment of rat skeletal myofibers with the OATP inhibitor estrone sulfate afforded protection against the toxicity of the hydrophilic and lipophilic
statins pravastatin and fluvastatin, respectively.57
The known statin efflux transporters, namely P-gp, MRP2
and BCRP are not expressed in human skeletal muscle
(Figure 1A). However, isoforms of the MRP transporter
family such as MRP1, MRP4, and MRP5 are highly expressed in skeletal muscle, although previous to this report,
their capacity for statin efflux was unknown. Here, we
demonstrate that the 3 human skeletal muscle MRPs (MRP1,
MRP4, and MRP5) transport rosuvastatin and/or atorvastatin.
These transporters are expressed on the sarcolemmal membrane of muscle fibers, indicating a protective role against
intracellular statin accumulation. There is wide substrate
overlap among MRPs,58 and this is certainly also the case for
statins that are transported by the skeletal muscle MRPs,
albeit at differing efficiencies. Recently, a role for rat Mrp1 in
statin-induced myopathy has been suggested in studies that
demonstrate precipitation of rosuvastatin-mediated skeletal
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Figure 6. Statin accumulation in HSMM cells after
adenoviral transduction of MRP1 and OATP2B1. A,
Immunofluorescence localization of MRP1 or
OATP2B1 (green) and nuclei (blue) in HSMM cells
after adenoviral infection with Ad-LacZ, Ad-MRP1,
Ad-OATP2B1, or Ad-OATP2B1 and Ad-MRP1 in
differentiated HSMM cells using confocal microscopy. Scale bar⫽50 m. B, Intracellular accumulation of [3H]rosuvastatin and [3H]atorvastatin in
HSMM cells after adenoviral overexpression of
OATP2B1 and MRP1. Results are presented as
femtomoles per microgram of protein⫾SEM (n⫽4).
***P⬍0.001 compared with no virus, Ad-LacZ, or
Ad-MRP1; ††P⬍0.01, †††P⬍0.001 compared with
Ad-OATP2B1; ‡P⬍0.05, ‡‡‡P⬍0.001 compared
with Ad-MRP1.

Downloaded from http://ahajournals.org by on June 21, 2022

muscle toxicity in rats cotreated with the MRP inhibitor,
probenecid.59 Interpretation of these findings remains difficult for a number of reasons, including a lack of demonstration that rat Mrp1 transports rosuvastatin, absence of Mrp1
expression data in tissues such as skeletal muscle, and a
deficiency of information regarding differences in plasma
and tissue concentrations of rosuvastatin after probenecid
cotreatment.59
The dynamic interplay between uptake and efflux transporter activities likely controls muscle fiber statin concentrations, which determines susceptibility to toxicity. We have
shown that the toxicity of rosuvastatin and atorvastatin in
primary human skeletal muscle cells is dependent on the
achieved intracellular drug concentrations. This is highlighted
by the findings that reduction of cellular statin accumulation
by MRP1 overexpression in cultured skeletal muscle cells
heterologously expressing OATP2B1 (Figure 6B) afforded
cytoprotection against statin exposure (Figure 7C and 7D). In
the guinea pig, skeletal muscle concentrations of rosuvastatin
and atorvastatin are less than 10% of that found in plasma,
suggesting that the balance is tipped toward higher efflux
than uptake activity.60 In our evaluation of the literature, the
plasma-to-skeletal muscle concentration ratio of statins in
humans is not known, but this value will undoubtedly be
dependent on the relative expression and intrinsic activities of
the attendant uptake (OATP2B1) and efflux (MRP1, MRP4,
MRP5) transporters. The present results would also suggest
that drug–statin interactions occurring not only at the level of
the hepatocyte cell membrane but also in skeletal muscle
fibers could contribute to myopathy. Certainly, a number of

clinically used drugs are substrates/inhibitors of the here
identified skeletal muscle statin transporters (Figures 3 and
5B).61,62 Our data suggest that skeletal muscle statin uptake
by OATP2B1 can be inhibited by concomitantly administered
drugs such as gemfibrozil, fenofibrate, and glyburide (Figure
3). This finding could be considered contradictory to the
increased risk of statin myopathy in patients cotreated with
gemfibrozil. However, it should be mentioned that the gemfibrozil inhibits hepatic statin clearance to increase systemic
statin exposure and there remains the possibility that inhibition of skeletal muscle efflux transport could offset the
protection provided by OATP2B1 inhibition. Indeed, we
demonstrate that statin efflux can be blocked by concurrent
treatment of HSMM cells with known inhibitors of MRPs
(Figure 5B). Moreover, one must consider not only pharmacokinetic but also pharmacodynamic interactions in
extrapolating the current transport inhibition findings to
myopathy risk.
There are limitations with the differentiated HSMM cell
model for the study of statin toxicity. Firstly, although MRP1,
MRP4, and MRP5 are constitutively expressed in HSMM
cells, only MRP1 localized to the plasma membrane (Figure
5A). This is in contrast to immunofluorescence data that show
these MRPs are expressed on the sarcolemmal membrane of
intact skeletal muscle fibers (Figure 1C). It is for this reason
that we are only able to assess the effect of MRP1 but not
MRP4 or MRP5 on cytoprotection against statins in this
model of skeletal muscle. Furthermore, HSMM cells do not
natively express OATP2B1, as is found in vivo; hence, we
required viral gene delivery to assess the role of uptake
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Figure 7. Statin cytotoxicity in HSMM cells after adenoviral transduction of MRP1 and OATP2B1. A, Dose-dependent cellular viability
of HSMM cells after treatment with atorvastatin and rosuvastatin for 5 days, measured by intracellular ATP concentration. Results are
presented as percentages of DMSO control⫾SEM (2 independent experiments with 3 determinations per experiment). B, Cellular viability of HSMM cells after treatment with atorvastatin and rosuvastatin for 72 hours, measured by intracellular ATP concentration. Results
are presented as percentages of DMSO control⫾SEM (n⫽5). C, Cellular viability of HSMM cells after treatment with atorvastatin and
rosuvastatin for 72 hours, measured by formazan formation using a MTT assay. Results are presented as percentages of DMSO
control⫾SEM (n⫽4). D, Induction of apoptosis in HSMM cells after treatment with atorvastatin and rosuvastatin for 48 hours measured
by activation of caspase 3 and 7. Results are presented as percentages of DMSO control⫾SEM (n⫽4). *P⬍0.05, **P⬍0.01, ***P⬍0.001.

transport on statin toxicity. That OATP2B1 is not expressed
in HSMM cells compares well with other skeletal muscle
genes that we have found at very low levels in relation to
intact skeletal muscle, including creatine kinase M isoform
(Online Figure I). Therefore, in interpreting the present
toxicity findings, it should be considered that this in vitro
model of skeletal muscle differs phenotypically to muscle
fibers in vivo.
In conclusion, statin transporters are present in human
skeletal muscle that control intracellular drug exposure. We

propose a role for OATP2B1 in sensitizing skeletal muscle
cells to statin toxicity and that the novel statin efflux
transporters MRP1, MRP4, and MRP5 protect muscle from
toxicity. The dynamic functional interplay between these
uptake and efflux transporters in vivo likely determines risk
for statin-induced myopathy.
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